Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus

S. Ahmad, B. Lohman, M. Marthas, L. Giavedoni, Z. El-Amad, Nancy Haigwood, C. J. Scandella, M. B. Gardner, P. A. Luciw, T. Yilma

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

As a safe alternative to inactivated and live-attenuated whole-virus SIV vaccines, we have evaluated the potential of SIV(mac239) gp160 expressed by recombinant vaccinia virus (vSIVgp160) and baculovirus (bSIVgp160) to protectively immunize rhesus macaques against intravenous (iv) infection with pathogenic SIV(mac) isolates. Macaques were immunized with live vSIVgp160 and/or bSIVgp160 protein partially purified from insect cells. The challenge viruses, propagated in rhesus peripheral blood mononuclear cells, consisted of the molecular clone SIV(mac239) and another genetically similar, uncloned isolate, SIV(mac251). Although antibodies that bind gp130 were induced in all animals following immunization with SIVgp160, neutralizing antibodies were undetectable 1 week prior to virus challenge. These results differ from those for macaques vaccinated with inactivated, whole SIV. All animals became infected after iv inoculation with 1-10 AID50 of either challenge virus. For animals challenged with SIV(mac251), but not those challenged with SIV(mac239), the cell-free infectious virus load in plasma of vSIVgp160- primed, bSIVgp160-boosted macaques was significantly lower than in unimmunized controls at 2 weeks postchallenge. Virus virulence, immunization regimen, and challenge with homologous or heterologous virus are factors critical to the outcome of the study. Immunization with surface glycoprotein may not necessarily provide protective immunity against infection but may reduce virus load. The relationship between reduction in virus load by vaccination and delay in onset of disease remains to be determined.

Original languageEnglish (US)
Pages (from-to)195-204
Number of pages10
JournalAIDS Research and Human Retroviruses
Volume10
Issue number2
StatePublished - 1994
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
Macaca mulatta
Viruses
Macaca
Immunization
SAIDS Vaccines
Vaccinia virus
Baculoviridae
Membrane Glycoproteins
Infection
Neutralizing Antibodies
Virulence
Insects
Immunity
Blood Cells
Vaccination
Clone Cells
Outcome Assessment (Health Care)
Antibodies

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. / Ahmad, S.; Lohman, B.; Marthas, M.; Giavedoni, L.; El-Amad, Z.; Haigwood, Nancy; Scandella, C. J.; Gardner, M. B.; Luciw, P. A.; Yilma, T.

In: AIDS Research and Human Retroviruses, Vol. 10, No. 2, 1994, p. 195-204.

Research output: Contribution to journalArticle

Ahmad, S, Lohman, B, Marthas, M, Giavedoni, L, El-Amad, Z, Haigwood, N, Scandella, CJ, Gardner, MB, Luciw, PA & Yilma, T 1994, 'Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus', AIDS Research and Human Retroviruses, vol. 10, no. 2, pp. 195-204.
Ahmad, S. ; Lohman, B. ; Marthas, M. ; Giavedoni, L. ; El-Amad, Z. ; Haigwood, Nancy ; Scandella, C. J. ; Gardner, M. B. ; Luciw, P. A. ; Yilma, T. / Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. In: AIDS Research and Human Retroviruses. 1994 ; Vol. 10, No. 2. pp. 195-204.
@article{cadb6c3c2e6f45e7b99772d5f206de9e,
title = "Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus",
abstract = "As a safe alternative to inactivated and live-attenuated whole-virus SIV vaccines, we have evaluated the potential of SIV(mac239) gp160 expressed by recombinant vaccinia virus (vSIVgp160) and baculovirus (bSIVgp160) to protectively immunize rhesus macaques against intravenous (iv) infection with pathogenic SIV(mac) isolates. Macaques were immunized with live vSIVgp160 and/or bSIVgp160 protein partially purified from insect cells. The challenge viruses, propagated in rhesus peripheral blood mononuclear cells, consisted of the molecular clone SIV(mac239) and another genetically similar, uncloned isolate, SIV(mac251). Although antibodies that bind gp130 were induced in all animals following immunization with SIVgp160, neutralizing antibodies were undetectable 1 week prior to virus challenge. These results differ from those for macaques vaccinated with inactivated, whole SIV. All animals became infected after iv inoculation with 1-10 AID50 of either challenge virus. For animals challenged with SIV(mac251), but not those challenged with SIV(mac239), the cell-free infectious virus load in plasma of vSIVgp160- primed, bSIVgp160-boosted macaques was significantly lower than in unimmunized controls at 2 weeks postchallenge. Virus virulence, immunization regimen, and challenge with homologous or heterologous virus are factors critical to the outcome of the study. Immunization with surface glycoprotein may not necessarily provide protective immunity against infection but may reduce virus load. The relationship between reduction in virus load by vaccination and delay in onset of disease remains to be determined.",
author = "S. Ahmad and B. Lohman and M. Marthas and L. Giavedoni and Z. El-Amad and Nancy Haigwood and Scandella, {C. J.} and Gardner, {M. B.} and Luciw, {P. A.} and T. Yilma",
year = "1994",
language = "English (US)",
volume = "10",
pages = "195--204",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus

AU - Ahmad, S.

AU - Lohman, B.

AU - Marthas, M.

AU - Giavedoni, L.

AU - El-Amad, Z.

AU - Haigwood, Nancy

AU - Scandella, C. J.

AU - Gardner, M. B.

AU - Luciw, P. A.

AU - Yilma, T.

PY - 1994

Y1 - 1994

N2 - As a safe alternative to inactivated and live-attenuated whole-virus SIV vaccines, we have evaluated the potential of SIV(mac239) gp160 expressed by recombinant vaccinia virus (vSIVgp160) and baculovirus (bSIVgp160) to protectively immunize rhesus macaques against intravenous (iv) infection with pathogenic SIV(mac) isolates. Macaques were immunized with live vSIVgp160 and/or bSIVgp160 protein partially purified from insect cells. The challenge viruses, propagated in rhesus peripheral blood mononuclear cells, consisted of the molecular clone SIV(mac239) and another genetically similar, uncloned isolate, SIV(mac251). Although antibodies that bind gp130 were induced in all animals following immunization with SIVgp160, neutralizing antibodies were undetectable 1 week prior to virus challenge. These results differ from those for macaques vaccinated with inactivated, whole SIV. All animals became infected after iv inoculation with 1-10 AID50 of either challenge virus. For animals challenged with SIV(mac251), but not those challenged with SIV(mac239), the cell-free infectious virus load in plasma of vSIVgp160- primed, bSIVgp160-boosted macaques was significantly lower than in unimmunized controls at 2 weeks postchallenge. Virus virulence, immunization regimen, and challenge with homologous or heterologous virus are factors critical to the outcome of the study. Immunization with surface glycoprotein may not necessarily provide protective immunity against infection but may reduce virus load. The relationship between reduction in virus load by vaccination and delay in onset of disease remains to be determined.

AB - As a safe alternative to inactivated and live-attenuated whole-virus SIV vaccines, we have evaluated the potential of SIV(mac239) gp160 expressed by recombinant vaccinia virus (vSIVgp160) and baculovirus (bSIVgp160) to protectively immunize rhesus macaques against intravenous (iv) infection with pathogenic SIV(mac) isolates. Macaques were immunized with live vSIVgp160 and/or bSIVgp160 protein partially purified from insect cells. The challenge viruses, propagated in rhesus peripheral blood mononuclear cells, consisted of the molecular clone SIV(mac239) and another genetically similar, uncloned isolate, SIV(mac251). Although antibodies that bind gp130 were induced in all animals following immunization with SIVgp160, neutralizing antibodies were undetectable 1 week prior to virus challenge. These results differ from those for macaques vaccinated with inactivated, whole SIV. All animals became infected after iv inoculation with 1-10 AID50 of either challenge virus. For animals challenged with SIV(mac251), but not those challenged with SIV(mac239), the cell-free infectious virus load in plasma of vSIVgp160- primed, bSIVgp160-boosted macaques was significantly lower than in unimmunized controls at 2 weeks postchallenge. Virus virulence, immunization regimen, and challenge with homologous or heterologous virus are factors critical to the outcome of the study. Immunization with surface glycoprotein may not necessarily provide protective immunity against infection but may reduce virus load. The relationship between reduction in virus load by vaccination and delay in onset of disease remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0028220153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028220153&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 195

EP - 204

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -